Research on GLP-1s for psoriasis is still in its early stages, but some small studies have shown promise. “There’s growing evidence that GLP-1s may reduce systemic inflammation, which plays a major role in psoriasis,” says Hannah Kopelman, DO, a dermatologist in New York City who treats people with psoriasis.

In one case study, researchers gave GLP-1s to a 73-year-old man with type 2 diabetes and psoriasis. Four months after starting semaglutide (Ozempic), he had seen a dramatic improvement in psoriasis symptoms and reported a much higher quality of life.

Other studies on small groups have found the same — GLP-1s improve psoriasis symptoms…

Read the full article at EVERYDAYHEALTH.COM